AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8493761 — intervention group
Group type: EXPERIMENTAL
Intervention: Human interferon alpha (HuIFN‐alpha) administered orally
Number of subjects: 0
Study 8493761 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 0
Study 31533854 — intervention group
Group type: EXPERIMENTAL
Intervention: Baduanjin exercise (12-week supervised training, 1 hour per day, 4 days per week)
Number of subjects: 120
Study 31533854 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific exercise intervention, maintain original lifestyle)
Number of subjects: 120
Study 30423680 — intervention group
Group type: EXPERIMENTAL
Intervention: Bledsoe Thruster brace
Number of subjects: 100
Study 30423680 — intervention group
Group type: COMPARATOR
Intervention: SofTec OA brace
Number of subjects: 100
Study 25350228 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic pectopexy
Number of subjects: 85
Study 25350228 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic sacropexy
Number of subjects: 85
Study 23690976 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (n=28)
Number of subjects: 86
Study 23690976 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training (n=30)
Number of subjects: 86
Study 23690976 — intervention group
Group type: COMPARATOR
Intervention: Balance and tone (control group, n=28)
Number of subjects: 86
Study 22166001 — intervention group
Group type: EXPERIMENTAL
Intervention: IPTc + HMM
Number of subjects: 1000
Study 22166001 — intervention group
Group type: COMPARATOR
Intervention: HMM
Number of subjects: 1000
Study 18541001 — intervention group
Group type: EXPERIMENTAL
Intervention: PICC
Number of subjects: 60
Study 18541001 — intervention group
Group type: COMPARATOR
Intervention: PC
Number of subjects: 60
Study 16724169 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release oxybutynin, 10 mg daily
Number of subjects: 0
Study 16724169 — intervention group
Group type: COMPARATOR
Intervention: Extended-release tolterodine, 4 mg daily
Number of subjects: 0
Study 12563548 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational family intervention
Number of subjects: 326
Study 12563548 — intervention group
Group type: COMPARATOR
Intervention: Medication alone
Number of subjects: 326
Study 12563548 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 326
Study 10971469 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 100 microg
Number of subjects: 8
Study 10971469 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 400 microg
Number of subjects: 8
Study 10971469 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 9000925 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound assessment chart
Number of subjects: 0
Study 9000925 — intervention group
Group type: COMPARATOR
Intervention: Standard documentation methods
Number of subjects: 0
Study 1623653 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 30
Study 1623653 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 6206316 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide (IND) 2.5 mg q am
Number of subjects: 17
Study 6206316 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCT) 50 mg q am
Number of subjects: 17
Study 6206316 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 30809631 — intervention group
Group type: EXPERIMENTAL
Intervention: Originator infliximab
Number of subjects: 2239
Study 30809631 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 2239
Study 30554233 — intervention group
Group type: EXPERIMENTAL
Intervention: 22‐oxa‐calcitriol (50,000 IU/week)
Number of subjects: 369
Study 30554233 — intervention group
Group type: COMPARATOR
Intervention: Calcitriol (50,000 IU/week)
Number of subjects: 369
Study 30554233 — intervention group
Group type: COMPARATOR
Intervention: Lactose powder (placebo)
Number of subjects: 369
Study 26879816 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemisinin conventional formulation (160 mg)
Number of subjects: 15
Study 26879816 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemisinin conventional formulation (500 mg)
Number of subjects: 15
Study 26879816 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemisinin micronized formulation (160 mg)
Number of subjects: 15
Study 26879816 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemisinin micronized formulation (160 mg) with piperaquine phosphate (360 mg)
Number of subjects: 15
Study 26879816 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing dose of artemisinin
Number of subjects: 15
Study 24460845 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus the NHS Direct Healthlines Service (intervention group)
Number of subjects: 1200
Study 24460845 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 1200
Study 22231705 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA combined with Tongdan Decoction
Number of subjects: 60
Study 22231705 — intervention group
Group type: COMPARATOR
Intervention: UDCA alone (Control)
Number of subjects: 60
Study 19665340 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselling with a decision aid (DA)
Number of subjects: 0
Study 19665340 — intervention group
Group type: COMPARATOR
Intervention: Routine counselling
Number of subjects: 0
Study 17980418 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide
Number of subjects: 311
Study 17980418 — intervention group
Group type: EXPERIMENTAL
Intervention: T2206C SNP
Number of subjects: 311
Study 14700510 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (amlodipine 5 mg + benazepril 20 mg)
Number of subjects: 106
Study 14700510 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (10 mg)
Number of subjects: 106
Study 14700510 — intervention group
Group type: COMPARATOR
Intervention: Benazepril (40 mg)
Number of subjects: 106
Study 12473867 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan 80 mg
Number of subjects: 60
Study 12473867 — intervention group
Group type: EXPERIMENTAL
Intervention: hydrochlorothiazide (HCTZ) 25 mg
Number of subjects: 60
Study 12473867 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study 12473867 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan vs HCTZ
Number of subjects: 60
Study 12473867 — intervention group
Group type: COMPARATOR
Intervention: valsartan vs placebo
Number of subjects: 60
Study 9440779 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy using standardized D. farinae antigen
Number of subjects: 60
Study 2776953 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracervical gel containing 50 mg 17 beta‐oestradiol
Number of subjects: 28
Study 2776953 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 28
Study 768851 — intervention group
Group type: EXPERIMENTAL
Intervention: L-asparaginase 100 U/kg
Number of subjects: 22
Study 768851 — intervention group
Group type: EXPERIMENTAL
Intervention: L-asparaginase 500 U/kg
Number of subjects: 22
Study 768851 — intervention group
Group type: EXPERIMENTAL
Intervention: L-asparaginase 1500 U/kg
Number of subjects: 22
Study 768851 — intervention group
Group type: EXPERIMENTAL
Intervention: L-asparaginase (all doses)
Number of subjects: 22
Study 31027915 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Number of subjects: 402
Study 31027915 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 402
Study 28092401 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron (ferric carboxymaltose)
Number of subjects: 116
Study 28092401 — intervention group
Group type: COMPARATOR
Intervention: Oral iron (ferrous sulphate)
Number of subjects: 116
Study 25720104 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (continuous negative pressure of -80 mmHg)
Number of subjects: 80
Study 25720104 — intervention group
Group type: COMPARATOR
Intervention: Conventional dressings (control group)
Number of subjects: 80
Study 25720104 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy
Number of subjects: 80
Study 23390123 — intervention group
Group type: EXPERIMENTAL
Intervention: DDD pacing at 60 ppm
Number of subjects: 101
Study 23390123 — intervention group
Group type: COMPARATOR
Intervention: DDI pacing at 30 ppm
Number of subjects: 101
Study 21086117 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem (Zp) 10 mg
Number of subjects: 16
Study 21086117 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone (Zc) 7.5 mg
Number of subjects: 16
Study 21086117 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 19940299 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 87
Study 19940299 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 16963343 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric diet with fiber-rich whole-grain cereals plus exercise
Number of subjects: 134
Study 16963343 — intervention group
Group type: COMPARATOR
Intervention: Exercise only
Number of subjects: 134
Study 14599046 — intervention group
Group type: EXPERIMENTAL
Intervention: GOS/FOS mixture
Number of subjects: 90
Study 10889149 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole, amoxicillin, and clarithromycin (OAC) for 1 week; n = 295
Number of subjects: 587
Study 10889149 — intervention group
Group type: COMPARATOR
Intervention: Placebo; n = 292
Number of subjects: 587
Study 8737958 — intervention group
Group type: EXPERIMENTAL
Intervention: trimetazidine 20 mg tid
Number of subjects: 149
Study 8737958 — intervention group
Group type: COMPARATOR
Intervention: propranolol 40 mg tid
Number of subjects: 149
Study 1568427 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid electrode (0.5 mg dexamethasone)
Number of subjects: 20
Study 1568427 — intervention group
Group type: COMPARATOR
Intervention: Electrode without steroid
Number of subjects: 20
Study 1568427 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid electrode
Number of subjects: 20
Study 2860153 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal irrigation with low molecular weight povidone-iodine solution (PVP-I LMW)
Number of subjects: 75
Study 2860153 — intervention group
Group type: COMPARATOR
Intervention: Saline irrigation (Control)
Number of subjects: 75
Study 2860153 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum iodine levels in 'Betadine LMW' patients
Number of subjects: 75
Study 2860153 — intervention group
Group type: COMPARATOR
Intervention: Serum iodine levels in control patients
Number of subjects: 75
Study 30539285 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tranexamic acid (TXA) 1g
Number of subjects: 158
Study 30539285 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical fibrin sealant (FS) 10 ml
Number of subjects: 158
Study 30539285 — intervention group
Group type: COMPARATOR
Intervention: Usual haemostasis (Control)
Number of subjects: 158
Study 27986480 — intervention group
Group type: EXPERIMENTAL
Intervention: vonapanitase 10 μg
Number of subjects: 151
Study 27986480 — intervention group
Group type: EXPERIMENTAL
Intervention: vonapanitase 30 μg
Number of subjects: 151
Study 27986480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study 26306970 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mM calcium bath
Number of subjects: 26
Study 26306970 — intervention group
Group type: COMPARATOR
Intervention: 1.25 mM calcium bath
Number of subjects: 26
Study 26306970 — intervention group
Group type: EXPERIMENTAL
Intervention: Both calcium baths
Number of subjects: 26
Study 23902670 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized written asthma action plan (WAAP)
Number of subjects: 91
Study 23902670 — intervention group
Group type: COMPARATOR
Intervention: Standard care (no WAAP)
Number of subjects: 91
Study 21063689 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual stimuli presented at the same spatial location as the pain
Number of subjects: 0
Study 21063689 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual stimuli presented at a different spatial location than the pain
Number of subjects: 0
Study 19143951 — intervention group
Group type: EXPERIMENTAL
Intervention: One parent present
Number of subjects: 0
Study 19143951 — intervention group
Group type: COMPARATOR
Intervention: Two parents present
Number of subjects: 0
Study 17695214 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg of cyclamate and 22.5 mg of saccharine
Number of subjects: 1
Study 17695214 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study 15147226 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol gel as an adjunct to handwashing
Number of subjects: 253
Study 15147226 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard hand hygiene unit)
Number of subjects: 253
Study 15147226 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (alcohol gel with handwashing)
Number of subjects: 253
Study 11799282 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser fluorescence (LF) system (DIAGNOdent)
Number of subjects: 170
Study 11799282 — intervention group
Group type: COMPARATOR
Intervention: Visual caries scoring system
Number of subjects: 170
Study 9579432 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Number of subjects: 905
Study 9579432 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin
Number of subjects: 905
Study 8087484 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical injection
Number of subjects: 100
Study 8087484 — intervention group
Group type: COMPARATOR
Intervention: Hand injection
Number of subjects: 100
Study 8087484 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 100
Study 2675668 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylcholine injected at different speeds (20 mg/s, 8 mg/s, 4 mg/s, 2 mg/s, 1 mg/s)
Number of subjects: 60
Study 2675668 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylcholine injected at different speeds
Number of subjects: 60
Study 788751 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral indoramin
Number of subjects: 0
Study 788751 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous indoramin
Number of subjects: 0
Study 31303153 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombectomy in direct patients
Number of subjects: 206
Study 31303153 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombectomy in transfer patients
Number of subjects: 206
Study 31303153 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 206
Study 29798346 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation group (patients with nasal local allergy symptoms)
Number of subjects: 60
Study 29798346 — intervention group
Group type: COMPARATOR
Intervention: Allergic Rhinitis (AR) group
Number of subjects: 60
Study 29798346 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers group
Number of subjects: 60
Study 26461821 — intervention group
Group type: EXPERIMENTAL
Intervention: Crisaborole topical ointment, 2%
Number of subjects: 25
Study 26461821 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 25
Study 22771085 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional alar base cinch suture (Group I)
Number of subjects: 62
Study 22771085 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-septal alar base cinch suture (Group II)
Number of subjects: 62
Study 22771085 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Group I and Group II
Number of subjects: 62
Study 21810253 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored activity pacing intervention led by occupational therapists
Number of subjects: 0
Study 21810253 — intervention group
Group type: COMPARATOR
Intervention: General activity pacing
Number of subjects: 0
Study 21810253 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 21810253 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored activity pacing intervention
Number of subjects: 0
Study 19902498 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian multivariate model for spatial binary data using random effects autologistic regression
Number of subjects: 0
Study 16920656 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy (NRT)
Number of subjects: 346
Study 16920656 — intervention group
Group type: EXPERIMENTAL
Intervention: NRT plus a behavioral intervention
Number of subjects: 346
Study 16920656 — intervention group
Group type: COMPARATOR
Intervention: Control group (smokers)
Number of subjects: 346
Study 16920656 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis (highly educated patients)
Number of subjects: 346
Study 16920656 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis (coronary artery disease, low education)
Number of subjects: 346
Study 16920656 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis (peripheral arterial disease, low nicotine dependency)
Number of subjects: 346
Study 15580167 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 12
Study 15580167 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 12
Study 11743836 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab 300 mg
Number of subjects: 536
Study 11743836 — intervention group
Group type: COMPARATOR
Intervention: Omalizumab (all dosages)
Number of subjects: 536
Study 11743836 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 536
Study 9400905 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol (100 mg twice daily)
Number of subjects: 44
Study 9400905 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg slow-release twice daily)
Number of subjects: 44
Study 9400905 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (12.5 mg twice daily)
Number of subjects: 44
Study 8101300 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus dipyridamole (5 mg/kg per 24 h intravenously for 28 h, followed by 200 mg twice daily)
Number of subjects: 948
Study 8101300 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (50 mg per day)
Number of subjects: 948
Study 8101300 — intervention group
Group type: COMPARATOR
Intervention: Oral anticoagulants (desired prothrombin time range 2.8-4.8 international normalised ratio)
Number of subjects: 948
Study 8101300 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus dipyridamole
Number of subjects: 948
Study 8101300 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 948
Study 8101300 — intervention group
Group type: COMPARATOR
Intervention: Oral anticoagulants
Number of subjects: 948
Study 6875209 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulfate (400 mg/day for one month)
Number of subjects: 0
Study 6875209 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31794163 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezocision-assisted flapless corticotomy
Number of subjects: 42
Study 31794163 — intervention group
Group type: COMPARATOR
Intervention: Control group (no piezocision)
Number of subjects: 42
Study 28872915 — intervention group
Group type: EXPERIMENTAL
Intervention: Edaravone
Number of subjects: 25
Study 28872915 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 27470506 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall adherence to the CONSORT for Abstracts checklist
Number of subjects: 463
Study 27470506 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence rate for The Lancet
Number of subjects: 463
Study 27470506 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence rate for NEJM
Number of subjects: 463
Study 27470506 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence rates to 8 checklist items
Number of subjects: 463
Study 24401481 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC)
Number of subjects: 30
Study 24401481 — intervention group
Group type: COMPARATOR
Intervention: Ologen™ implant (OLO)
Number of subjects: 30
Study 22615118 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal sexual attitudes
Number of subjects: 0
Study 22615118 — intervention group
Group type: EXPERIMENTAL
Intervention: High situational risk
Number of subjects: 0
Study 22615118 — intervention group
Group type: EXPERIMENTAL
Intervention: Low situational risk
Number of subjects: 0
Study 18785052 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-grains bread (M-Grains)
Number of subjects: 12
Study 18785052 — intervention group
Group type: EXPERIMENTAL
Intervention: Wholemeal bread with oatmeal (WM-Oat)
Number of subjects: 12
Study 18785052 — intervention group
Group type: EXPERIMENTAL
Intervention: Wholemeal bread (WM)
Number of subjects: 12
Study 18785052 — intervention group
Group type: EXPERIMENTAL
Intervention: White bread (WB)
Number of subjects: 12
Study 17503753 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary uridine supplement (36 g three times a day for 10 consecutive days/month)
Number of subjects: 20
Study 17503753 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 16530147 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous reminders (as needed)
Number of subjects: 1662
Study 16530147 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited reminders (up to 3)
Number of subjects: 1662
Study 16530147 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 1662
Study 15474756 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 levels >= 20 pmol/l
Number of subjects: 345
Study 15474756 — intervention group
Group type: COMPARATOR
Intervention: E2 levels < 20 pmol/l
Number of subjects: 345
Study 10776469 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (200 mg i/v before surgical incision and a second dose after 12 hrs), n = 45
Number of subjects: 155
Study 10776469 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime (750 mg i/v before surgical incision and a second dose after 12 hrs), n = 45
Number of subjects: 155
Study 10776469 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (200 mg i/v post operatively, 12 hourly for 2 days followed by oral 500 mg twice daily for 3 days), n = 35
Number of subjects: 155
Study 10776469 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic, n = 30
Number of subjects: 155